Clinical Trials Logo
  1. Home
  2. Scalp Psoriasis
  3. NCT02933502

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Scalp Psoriasis Clinical Trial

Official title:
An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis

Clinical Trial Summary

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

Clinical Trial Description

- Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis.

- Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02933502
Study type Interventional
Source Taro Pharmaceuticals USA
Contact
Status Completed
Phase Phase 2
Start date July 11, 2016
Completion date January 2, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT00400725 - Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis Phase 3
Completed NCT01195831 - Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis Phase 3
Completed NCT03880357 - To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis Phase 1
Completed NCT03331523 - To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis Phase 3
Completed NCT04801433 - Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis N/A
Completed NCT01120223 - Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Phase 2
Completed NCT03897088 - Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis Phase 3
Completed NCT02932462 - Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis Phase 3
Completed NCT02933866 - Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis Phase 3
Completed NCT05872256 - A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis Phase 4
Active, not recruiting NCT05272150 - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis Phase 3
Completed NCT01052467 - Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel) N/A
Completed NCT04243486 - A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis Phase 2
Recruiting NCT02749656 - Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis Phase 3
Completed NCT02078297 - IL-17 Role in Variants of Psoriasis N/A
Completed NCT00438399 - Subject Preference for Scalp Psoriasis Treatment Phase 3
Completed NCT05028582 - Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) Phase 3
Completed NCT01914627 - Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis Phase 2
Not yet recruiting NCT01558310 - A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Phase 4
Recruiting NCT05969223 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis Phase 4